Fierce Biotech August 28, 2024
Bayer executives were keen to stress to Fierce this summer that the German pharma giant’s appetite for dealmaking hasn’t been curbed by a groupwide restructuring. Its latest cancer-focused collaboration suggests Bayer has indeed retained a taste for intriguing new modalities.
The company has signed a deal worth more than half a billion biobucks to partner up on two programs with NextRNA Therapeutics, a biotech working on long noncoding RNA (lncRNA)-driven diseases. The collaboration will focus on oncology indications with high unmet need, the companies said in an Aug. 28 news release.
NextRNA will be in line for a total of $547 million across upfront and near-term milestone payments, research funding and development and commercial milestone payments, on top of tiered...
Today's Sponsors
Today's Sponsor